Analyst Price Targets — ZYME
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 26, 2026 10:09 am | — | H.C. Wainwright | $55.00 | $27.47 | TheFly | Zymeworks price target raised to $55 from $51 at H.C. Wainwright |
| August 26, 2026 8:21 am | — | Deutsche Bank | $32.00 | $27.47 | StreetInsider | Zymeworks (ZYME) Reiterated at Market Outperform by Citizens on FDA Approval for Zani |
| August 7, 2026 2:22 pm | Gregory Renza | Truist Financial | $32.00 | $23.77 | TheFly | Zymeworks price target raised to $32 from $31 at Truist |
| August 7, 2026 1:13 pm | — | Stifel Nicolaus | $46.00 | $24.11 | TheFly | Zymeworks price target lowered to $46 from $47 at Stifel |
| August 7, 2026 11:24 am | — | Wells Fargo | $40.00 | $23.13 | TheFly | Zymeworks price target raised to $40 from $37 at Wells Fargo |
| August 5, 2026 4:55 pm | — | H.C. Wainwright | $51.00 | $23.57 | TheFly | Zymeworks price target raised to $51 from $46 at H.C. Wainwright |
| July 7, 2026 1:15 pm | — | Truist Financial | $31.00 | $26.45 | TheFly | Zymeworks price target raised to $31 from $28 at Truist |
| June 30, 2026 10:24 am | — | Wells Fargo | $37.00 | $24.10 | TheFly | Zymeworks price target raised to $37 from $34 at Wells Fargo |
| June 9, 2026 10:08 am | Gregory Renza | Truist Financial | $28.00 | $23.93 | StreetInsider | Truist Securities Assumes Zymeworks (ZYME) at Buy |
| June 3, 2026 10:52 am | Andrew Berens | H.C. Wainwright | $46.00 | $24.11 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Zymeworks (ZYME) |
Latest News for ZYME
Zymeworks Inc. is transitioning from a development-stage biotech to a royalty-driven, revenue-generating platform following zanidatamab's FDA approval. Zanidatamab's first-line HER2+ gastroesophageal cancer approval expands the eligible patient population and unlocks a $250M milestone plus 10–20% tiered royalties. ZYME's near-term upside hinges on commercial execution, label expansions, and integrating durable…
Bank of America Corp DE lifted its stake in Zymeworks Inc. (NASDAQ: ZYME) by 164.5% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 236,754 shares of the company's stock after buying an additional 147,230 shares during the period. Bank
Jazz Pharmaceuticals' Ziihera wins FDA approval for first-line HER2-positive GEA, expanding its market and showing strong progression-free and survival benefits.
Deutsche Bank AG purchased a new stake in Zymeworks Inc. (NASDAQ: ZYME) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 397,190 shares of the company's stock, valued at approximately $10,383,000. Deutsche Bank AG owned approximately 0.54% of
Theravance's Q2 earnings match estimates. Cost cuts and a $929 million Zymeworks deal follow ampreloxetine's discontinuation.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ZYME.
U.S. House Trading
No House trades found for ZYME.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.